Study testing IRE treatment for early prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at whether a new type of procedure called IRE can treat certain MRI-visible prostate tumors in men with early-stage disease. You may be able to join if your cancer fits specific scan and biopsy features and you have not had prior prostate cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 40 or older
- Have a prostate lesion seen on MRI
- Your cancer should be early and limited to one main area (not widespread)
- Your PSA must be 20 or lower
- Have not had prostate cancer treatment before (no surgery, radiation, chemo, or hormone therapy)
- Be able to have an MRI safely (for example, no metal devices that block MRI; not too claustrophobic)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, non-surgical treatment called irreversible electroporation (IRE) for men with early-stage prostate cancer that hasn't spread. It uses short electrical pulses to destroy cancer cells while sparing healthy tissue nearby.
This trial tests a new focal treatment called IRE (irreversible electroporation) that uses electrical pulses to destroy prostate cancer cells while sparing healthy tissue. It is for men with intermediate-risk prostate cancer that has not spread outside the prostate gland.
This study uses a special kind of MRI to better “map” prostate cancer inside the prostate. Researchers compare the MRI results with the detailed tissue exam after prostate surgery to see how accurate the imaging is.
This trial uses advanced MRI scans and detailed tissue analysis to better detect prostate cancer. It is for people with confirmed prostate cancer who are already scheduled for prostate removal surgery.
This trial tests a stronger, more focused radiation dose to the main tumor inside the prostate using MRI guidance. It aims to improve control of intermediate-risk prostate cancer while possibly reducing side effects.
This trial compares two different ways to give focused radiation to the prostate in men with intermediate-risk prostate cancer. The goal is to see which approach works better and is safer for patients.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.